Russell Investments Group
NRIX icon

Russell Investments Group’s Nurix Therapeutics NRIX Stock Holding History

Russell Investments Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.5M Buy
185,524
+103,683
+127% +$1.77M ﹤0.01% 1573
2026
Q1 		$1.27M Buy
81,841
+18,359
+29% +$304K ﹤0.01% 2103
2025
Q4 		$1.2M Buy
63,482
+3,046
+5% +$43.8K ﹤0.01% 2131
2025
Q3 		$558K Buy
60,436
+57,922
+2,304% +$602K ﹤0.01% 2435
2025
Q2 		$28.6K Sell
2,514
-127,224
-98% -$1.37M ﹤0.01% 3116
2025
Q1 		$1.54M Buy
129,738
+93,993
+263% +$1.57M ﹤0.01% 1845
2024
Q4 		$673K Buy
35,745
+35,017
+4,810% +$803K ﹤0.01% 2173
2024
Q3 		$16.4K Sell
728
-2,745
-79% -$62.2K ﹤0.01% 2998
2024
Q2 		$72.5K Sell
3,473
-50,069
-94% -$780K ﹤0.01% 2694
2024
Q1 		$787K Buy
53,542
+23,044
+76% +$248K ﹤0.01% 2060
2023
Q4 		$315K Buy
30,498
+15
+0% +$103 ﹤0.01% 2337
2023
Q3 		$240K Sell
30,483
-5,073
-14% -$46.3K ﹤0.01% 2454
2023
Q2 		$355K Sell
35,556
-1,120
-3% -$11.4K ﹤0.01% 2329
2023
Q1 		$326K Buy
36,676
+12,587
+52% +$131K ﹤0.01% 2381
2022
Q4 		$264K Buy
24,089
+23,210
+2,641% +$280K ﹤0.01% 2500
2022
Q3 		$11K Buy
+879
New +$13.9K ﹤0.01% 2856
2021
Q3 		– Sell
-5,749
Closed -$152K – 3160
2021
Q2 		$152K Hold
5,749
– – ﹤0.01% 2976
2021
Q1 		$178K Buy
+5,749
New +$218K ﹤0.01% 2861

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $587M AUM 20.13% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Russell Investments Group's NRIX Position: Q2 2026 in Review

Russell Investments Group increased its Nurix Therapeutics (NRIX) stake by 127% in Q2 2026, buying an estimated $1.77M and bringing the position to 185,524 shares worth $4.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1573.

Russell Investments Group first reported a position in NRIX in Q1 2021 and has held it in 18 quarters since. 71 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Russell Investments Group held 185,524 shares of Nurix Therapeutics worth $4.5M as of Q2 2026.
  • Russell Investments Group bought 103,683 Nurix Therapeutics shares in Q2 2026, an estimated $1.77M.
  • Nurix Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #1573 holding.
  • Russell Investments Group first reported a position in Nurix Therapeutics in Q1 2021 and has held it in 18 quarters since.
  • 71 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.